Biopharma Business

Drug Delivery

Biogen to remain leader in neurodegenerative drugs

Roche’a anticipated approval of ocrelizumab will drive the company’s share of the market from <1% in 2016 to 15% by 2022, according to GBI Research The company’s report states that

Read Full Article

Upcoming Events

  • No upcoming events
AEC v1.0.4

The Magazine

New Subscriber

Subscribe Here